Bristol Myers Squibb Total Liabilities 2010-2023 | BMY
Bristol Myers Squibb total liabilities from 2010 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
- Bristol Myers Squibb total liabilities for the quarter ending March 31, 2023 were $62.395B, a 12.6% decline year-over-year.
- Bristol Myers Squibb total liabilities for 2022 were $65.702B, a 10.38% decline from 2021.
- Bristol Myers Squibb total liabilities for 2021 were $73.308B, a 9.05% decline from 2020.
- Bristol Myers Squibb total liabilities for 2020 were $80.599B, a 3.01% increase from 2019.
Bristol Myers Squibb Annual Total Liabilities
(Millions of US $) |
| 2022 |
$65,702 |
| 2021 |
$73,308 |
| 2020 |
$80,599 |
| 2019 |
$78,246 |
| 2018 |
$20,859 |
| 2017 |
$21,704 |
| 2016 |
$17,360 |
| 2015 |
$17,324 |
| 2014 |
$18,766 |
| 2013 |
$23,356 |
| 2012 |
$22,259 |
| 2011 |
$17,103 |
| 2010 |
$15,438 |
| 2009 |
$16,223 |
Bristol Myers Squibb Quarterly Total Liabilities
(Millions of US $) |
| 2023-03-31 |
$62,395 |
| 2022-12-31 |
$65,702 |
| 2022-09-30 |
$65,462 |
| 2022-06-30 |
$67,696 |
| 2022-03-31 |
$71,389 |
| 2021-12-31 |
$73,308 |
| 2021-09-30 |
$73,609 |
| 2021-06-30 |
$73,923 |
| 2021-03-31 |
$74,762 |
| 2020-12-31 |
$80,599 |
| 2020-09-30 |
$75,306 |
| 2020-06-30 |
$78,916 |
| 2020-03-31 |
$79,308 |
| 2019-12-31 |
$78,246 |
| 2019-09-30 |
$39,679 |
| 2019-06-30 |
$39,012 |
| 2019-03-31 |
$19,517 |
| 2018-12-31 |
$20,859 |
| 2018-09-30 |
$19,984 |
| 2018-06-30 |
$20,223 |
| 2018-03-31 |
$20,177 |
| 2017-12-31 |
$21,704 |
| 2017-09-30 |
$19,063 |
| 2017-06-30 |
$18,588 |
| 2017-03-31 |
$18,402 |
| 2016-12-31 |
$17,360 |
| 2016-09-30 |
$17,946 |
| 2016-06-30 |
$17,753 |
| 2016-03-31 |
$17,341 |
| 2015-12-31 |
$17,324 |
| 2015-09-30 |
$16,506 |
| 2015-06-30 |
$16,663 |
| 2015-03-31 |
$17,890 |
| 2014-12-31 |
$18,766 |
| 2014-09-30 |
$18,249 |
| 2014-06-30 |
$18,124 |
| 2014-03-31 |
$17,893 |
| 2013-12-31 |
$23,356 |
| 2013-09-30 |
$22,090 |
| 2013-06-30 |
$21,879 |
| 2013-03-31 |
$22,259 |
| 2012-12-31 |
$22,259 |
| 2012-09-30 |
$22,144 |
| 2012-06-30 |
$15,855 |
| 2012-03-31 |
$16,162 |
| 2011-12-31 |
$17,103 |
| 2011-09-30 |
$15,578 |
| 2011-06-30 |
$15,688 |
| 2011-03-31 |
$14,950 |
| 2010-12-31 |
$15,438 |
| 2010-09-30 |
$16,028 |
| 2010-06-30 |
$15,477 |
| 2010-03-31 |
$15,520 |
| 2009-12-31 |
$16,223 |
| 2009-09-30 |
$16,580 |
| 2009-06-30 |
$15,873 |
| 2009-03-31 |
$16,564 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$137.942B |
$46.159B |
|
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
|
